The average decline in cancer drugs after negotiations was 56.7 per cent

In June this year, the State Health Insurance Administration a new round of special negotiations on access to anti-cancer drugs began, 44 out-of-catalog exclusive anti-cancer drugs through expert review and voting selection, and the will of enterprises, the final 17 drugs were successfully negotiated.
10 October, the State Administration of Medical Security issued a Notice on the Inclusion of 17 Drugs in the Category B Of the National List of Essential Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drugs. Seventeer cancer drugs were included in the Medicare reimbursement list, an average decrease of 56.7 percent compared to the average retail price.the talks 9 varieties fell by more than 65
the health care negotiations involved 18 varieties from 12 companies. Sixteen are imported varieties and two are domestic varieties, including Aroteini, which is sunny, and Permen winter enzyme injections from Hengrui Pharmaceuticals.
found that the 17 anti-cancer drugs just released, including 12 solid tumor drugs and 5 blood tumor drugs, are clinically necessary, the efficacy of accurate, the needs of the insured urgent tumor treatment drugs, involving non-small cell lung cancer, kidney cancer, colorectal cancer, melanoma, lymphoma and other cancers. Novartra's phosphate reeds are not on the list.
17 negotiated drugs fell by an average of 56.7 per cent compared with the average retail price, and most imported drugs were negotiated to pay less than the market prices of neighbouring countries or regions, with an average of 36 per cent lower. Among them, the price reduction of more than 65% of the varieties include: achtinib, clotinib, Shonitini, Osetini, Nilotini, Paislopani, Seritini, Sitoxidini, Ibtini.Negotiation details Most of the anti-cancer drug departments "patent period" negotiations difficult
In June 2018, the State Health Insurance Administration just set up, in accordance with the State Council anti-cancer drug tax reduction work deployment, immediately launched the directory of anti-cancer drug health insurance access special negotiations. The experts of the negotiating expert group are drawn from the expert pool of the State Health Insurance Administration, from Shandong, Yunnan, Beijing, Jiangsu and other places, most of whom have participated in the provincial health insurance negotiations.
this negotiation of anti-cancer drugs, are necessary to treat blood tumors and solid tumors of high clinical value, high innovation, high patient benefits of drugs. Most of these drugs are still in the exclusive patent protection period, negotiations are very difficult.
Jinglin, director of the State Health Insurance Administration, said:
In this time included in the list of anti-cancer drugs are newly listed drugs in recent years, the patent survival period is still relatively long." Through the strategic purchase of these high-quality innovative drugs through health insurance, pharmaceutical companies can promote and promote increased investment in research and development, in order to develop more and better innovative drugs to benefit the vast number of patients. In
, for example, the treatment of colorectal cancer was mainly treated, and in the first round of national drug negotiations in 2017, there was citoxident anti-injection, but ultimately the negotiations failed. This time, for the NHS and businesses, both sides want to find a balance at what price they can negotiate successfully.
, the average price of a single anti-injection solution in 2017 was about 4,200 yuan, according to the data. The whole negotiation process lasted more than 30 minutes, and the two sides finally reached an agreement and signed a price agreement. The negotiated price was reduced from 4,200 yuan to 1,295 yuan. (New Kangjie)